0001104659-23-080099.txt : 20230711 0001104659-23-080099.hdr.sgml : 20230711 20230711203026 ACCESSION NUMBER: 0001104659-23-080099 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230707 FILED AS OF DATE: 20230711 DATE AS OF CHANGE: 20230711 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Deliargyris Efthymios CENTRAL INDEX KEY: 0001751617 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36792 FILM NUMBER: 231083088 MAIL ADDRESS: STREET 1: C/O PLX PHARMA,INC.8285 EL RIO STREET STREET 2: SUITE 210 CITY: HOUSTON STATE: TX ZIP: 77054 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cytosorbents Corp CENTRAL INDEX KEY: 0001175151 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 980373793 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 305 COLLEGE ROAD EAST CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: 973-329-8885 MAIL ADDRESS: STREET 1: 305 COLLEGE ROAD EAST CITY: PRINCETON STATE: NJ ZIP: 08540 FORMER COMPANY: FORMER CONFORMED NAME: MedaSorb Technologies CORP DATE OF NAME CHANGE: 20060807 FORMER COMPANY: FORMER CONFORMED NAME: GILDER ENTERPRISES INC DATE OF NAME CHANGE: 20020611 4 1 tm2321021-1_4seq1.xml OWNERSHIP DOCUMENT X0407 4 2023-07-07 0 0001175151 Cytosorbents Corp CTSO 0001751617 Deliargyris Efthymios C/O CYTOSORBENTS CORPORATION 305 COLLEGE ROAD EAST PRINCETON NJ 08540 0 1 0 0 Chief Medical Officer 0 Common Stock 2023-07-07 4 A 0 55000 0 A 331648 D Stock Option (right to buy) 3.53 2023-07-07 4 A 0 78000 0 A 2033-07-07 Common Stock 78000 78000 D Stock Option (right to buy) 3.53 2023-07-07 4 A 0 40000 0 A 2033-07-07 Common Stock 40000 40000 D These shares represent restricted stock units ("RSUs") which shall vest as to two-thirds of the award on the first anniversary of the date of grant and one-third of the award on the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date. Includes (a) (i) 120,000 RSUs granted on April 9, 2020 that will be settled into Common Stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"); (continued from footnote 2) (b) the following RSUs: (a) 20,000 RSUs granted on April 9, 2020 and unvested on the date hereof (these RSUs cliff vest on the fourth anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date); (b) 55,000 RSUs granted on August 10, 2022 and unvested on the date hereof (these RSUs vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date); and (c) 55,000 RSUs granted on July 7, 2023 and reported on this Form 4; and (continued from footnote 3) (c) 46,981 shares of Common Stock owned by the reporting person. These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first anniversary of the date of grant, one-fourth of the award on the second anniversary of the date of grant, and onefourth of the award on the third anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date. These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on each of the first anniversary of the date of grant and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date. /s/ Kathleen P. Bloch attorney-in-fact for Efthymios Deliargyris 2023-07-11